PRDM1 and lymphoma: Immunohistochemical analysis of Ki67 and a TUNEL assay on the retrieved RJ-Lym1 samples showed that the HSP70 inhibitor exerted a stronger inhibitory effect on the proliferation and survival of lymphoma cells in vivo than bortezomib under conditions in which both treatments similarly increased Blimp-1 levels (Fig. 7b).